Knee osteoarthritis(KOA)and osteoporosis(OP)"co-morbidity"is a chronic progressive disease,the incidence of which is higher in recent years.Exosomes have intercellular messenger functions,which play an important role in the development of KOA and OP"co-morbidity".This article recognized the"co-morbidity"between KOA and OP from the perspective of modern medicine and the"tendon","bone","liver"and"kidney"in TCM theories,systematically reviewed the indirect regulation of KOA and OP"co-morbidity"through exosomes,and explored the possible mechanisms of exosome-based treatment of KOA and OP"co-morbidity"through Chinese materia medica in terms of inflammation,MAPK pathway,bone remodeling and cartilage metabolism,and mitochondrial autophagy,with the aim to investigate the possible mechanisms of KOA and OP"co-morbidity",and provide new ideas for the treatment of KOA and OP"co-morbidity".

Knee osteoarthritis(KOA)and osteoporosis(OP)"co-morbidity"is a chronic progressive disease,the incidence of which is higher in recent years.Exosomes have intercellular messenger functions,which play an important role in the development of KOA and OP"co-morbidity".This article recognized the"co-morbidity"between KOA and OP from the perspective of modern medicine and the"tendon","bone","liver"and"kidney"in TCM theories,systematically reviewed the indirect regulation of KOA and OP"co-morbidity"through exosomes,and explored the possible mechanisms of exosome-based treatment of KOA and OP"co-morbidity"through Chinese materia medica in terms of inflammation,MAPK pathway,bone remodeling and cartilage metabolism,and mitochondrial autophagy,with the aim to investigate the possible mechanisms of KOA and OP"co-morbidity",and provide new ideas for the treatment of KOA and OP"co-morbidity".

Objective:To evaluate the efficacy and safety of Biapenem in very elderly patients(≥85 years old)with respiratory infections, and to provide a basis for rational use of Biapenem.Methods:A retrospective study was conducted on patients ≥85 years old, who had received Biapenem and undergone relevant laboratory tests from January 2016 to December 2017.Results:A total of 194 patients, with an average age of (88.5±3.1)years were enrolled.The rate of clinical effectiveness for infection treatment was 66.5%(129/194).Logistic regression analysis showed that blood urea nitrogen(BUN)≥8.2 mmol/L( OR=2.404, 95% CI: 1.425-4.065, P=0.001)and Biapenem monotherapy( OR=1.995, 95% CI: 1.175-3.386, P=0.006)were independent risk factors for treatment failure, while other factors, such as underlying diseases, body temperature, previous drug use, alanine aminotransferase levels and aspartate aminotransferase levels, showed no clear association with clinical outcomes.BUN showed significant elevations from pretreatment(8.6 ± 5.1)mmol/L to post-treatment(10.3 ± 9.8)mmol/L( t=-3.362, P=0.001).Adverse drug reactions were observed in 11.9%(23/194)patients, and all these were mild or intermediate. Conclusions:Biapenem is efficacious and safe when used for the treatment of respiratory infections in very elderly patients, and BUN level monitoring during treatment is recommended.